CagriSema for type 2 diabetes: what the REIMAGINE trials found

Three trials, three type 2 diabetes populations

CagriSema's obesity data has dominated the coverage so far. REDEFINE 1 showed 22.7% weight loss in adults without diabetes. REDEFINE 4 then put it against tirzepatide and lost, 23% to 25.5%. What got less attention is that Novo Nordisk ran an entirely separate trial program, REIMAGINE, testing the same drug specifically in people with type 2 diabetes. That data was preliminary at the ADA 2026 Scientific Sessions in June. It is now published in full, in The Lancet and The Lancet Diabetes & Endocrinology, and it tells a different story than the obesity headlines.

REIMAGINE is not one trial. It is three, each targeting a distinct group of people with type 2 diabetes: those newly diagnosed and untreated, those already on metformin, and those on basal insulin who have run out of easy options.

REIMAGINE 1: the drug-naive population

REIMAGINE 1 enrolled adults with type 2 diabetes inadequately controlled on diet and exercise alone, most with a short disease history, a median of 1.4 years. Over 40 weeks, CagriSema 2.4mg/2.4mg cut HbA1c by 1.8 percentage points more than placebo and produced 13.8% weight loss. More than half of participants, 57%, hit a composite goal of HbA1c at or below 6.5% plus at least 10% weight loss. Nearly one in four lost 20% or more of their body weight.

Those numbers matter because early, aggressive treatment in newly diagnosed type 2 diabetes tends to produce better long-term outcomes than slow titration through weaker drugs first. A therapy that gets more than half of drug-naive patients to a combined glycemic and weight target in under a year is a strong first-line case, assuming cost and access eventually allow it.

REIMAGINE 2: the head-to-head against semaglutide alone

This is the trial with the clearest commercial stakes. REIMAGINE 2 enrolled 2,728 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor, and randomized them across CagriSema, semaglutide alone, cagrilintide alone, and placebo over 68 weeks.

A 1.91-point HbA1c gap is large in diabetes terms. Most add-on therapies that make it to market move HbA1c by half a point to a point. Combined with a meaningfully larger weight loss than semaglutide alone, REIMAGINE 2 gives Novo Nordisk its strongest evidence yet that cagrilintide is not just an obesity add-on, it changes glycemic outcomes on its own terms.

REIMAGINE 3: adding CagriSema to basal insulin

REIMAGINE 3 targeted the hardest population: 274 adults with long-standing type 2 diabetes already on daily basal insulin, with or without metformin, and still not at target. This is a group where most add-on options either barely move HbA1c or force a hypoglycemia tradeoff by pushing insulin doses higher.

Over 40 weeks, adding CagriSema dropped average HbA1c from 8.8% to 6.5%, more than two full points, with weight loss up to 12%. Critically, the trial reported no increase in hypoglycemia and no need to escalate insulin dosing. For endocrinologists managing patients who have plateaued on insulin, a therapy that drops HbA1c by two points without the usual downside is a meaningfully different tool than what is currently available.

Why this matters more than another obesity trial

The GLP-1 conversation has been dominated by weight loss percentages for two years now, retatrutide's 28.3%, tirzepatide's 20.9%, CagriSema's 22.7%. Diabetes control is a separate outcome, and it is arguably the more consequential one for the roughly 38 million Americans living with type 2 diabetes, most of whom are not chasing a beach-body number so much as trying to avoid neuropathy, kidney damage, and cardiovascular events.

REIMAGINE reframes CagriSema as a diabetes drug that also produces significant weight loss, rather than a weight loss drug that happens to move blood sugar. That framing matters for how it eventually gets positioned, priced, and covered by insurance if and when it reaches approval.

What this does not settle

None of the three REIMAGINE trials ran CagriSema against tirzepatide in a diabetes population. Tirzepatide already carries an FDA-approved type 2 diabetes indication, backed by the SURPASS trial program and several years of real-world prescribing data. REIMAGINE proves CagriSema beats semaglutide alone and placebo. It does not prove CagriSema beats the drug that is already approved, already prescribed, and already available through telehealth programs.

The comparison REDEFINE 4 ran in obesity showed tirzepatide ahead by 2.5 points on weight loss. Whether that gap holds, narrows, or reverses in a diabetes-specific head-to-head is an open question REIMAGINE was not designed to answer.

When CagriSema might actually be available

The realistic timeline is that CagriSema reaches the market first for obesity, if the FDA approves the current filing, with a diabetes indication following later if Novo Nordisk pursues one based on REIMAGINE. Until then, tirzepatide and semaglutide remain the approved options for anyone managing type 2 diabetes today. If you are trying to decide between the two available drugs right now, the direct comparison is covered in semaglutide vs tirzepatide.